Clinical Trial Update: Assessment of the Contribution of Monophosphoryl Lipid A (MPL) to a Tree Pollen Allergy Vaccine [Phase 2]

View source ↗

Summary

A Phase 2 clinical trial evaluated the contribution of Monophosphoryl Lipid A (MPL) as an adjuvant to a tree pollen allergy vaccine; the study has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Allergic Rhinitis
• Pollen Allergy

Drugs mentioned

• Monophosphoryl Lipid A (Monophosphoryl Lipid A)
• Tree pollen allergy vaccine (MPL adjuvant)

Snippet

Sponsor: Allergy Therapeutics | Conditions: Type I Hypersensitivity | Phase 2 | Status: COMPLETED